Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-18030A |
Brand: | MCE |
CAS: | 2070009-30-0 |
MDL | - |
---|---|
Molecular Weight | 635.17 |
Molecular Formula | C29H39ClN6O6S |
SMILES | O=C([C@H]1[C@](C2)([H])C=C[C@]2([H])[C@H]1NC3=NC(NC4=CC=C5C(CC[C@@H](N6CCOCC6)CC5)=C4OC)=NC=C3Cl)N.O=S(C)(O)=O |
CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC 50 value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity [1] .
CEP-28122 mesylate salt (3-3000 nM; 48 hours) treatment leads to concentration-dependent growth inhibition of Karpas-299 and Sup-M2 cells in culture, associates with concentration-related caspase 3/7 activation
[1]
.
CEP-28122 mesylate salt (30-1000 nM; 2 hours) treatment leads to substantial suppression of phosphorylation of putative downstream effectors of ALK in Sup-M2 cells, indicating that the downstream signaling pathways are mediated by individual ALK fusion protein
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [1]
Cell Line: | Karpas-299, Sup-M2, Toledo and HuT-102 cells |
Concentration: | 10 nM, 100 nM, 1000 nM, 10000 nM |
Incubation Time: | 48 hours |
Result: | Treatment led to concentration-dependent growth inhibition of Karpas-299 and Sup-M2 cells in culture. |
Western Blot Analysis [1]
Cell Line: | Sup-M2 cells |
Concentration: | 30 nM, 100 nM, 300 nM, 1000 nM |
Incubation Time: | 2 hours |
Result: | Resulted in substantial suppression of phosphorylation of putative downstream effectors of ALK, including Stat-3, Akt, and ERK1/2 in Sup-M2 cells. |
CEP-28122 mesylate salt (3-30 mg/kg; oral gavage; twice a day; 12 days) produces dose-dependent antitumor activity in Sup-M2 subcutaneous tumor xenografts in SCID mice.In contrast, CEP-28122 has no antitumor activity in nu / nu mice bearing HCT116, suggesting that the antitumor activity of CEP-28122 in NPM-ALK–positive Sup-M2 tumor models is due to sustained NPM-ALK inhibition in tumors [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Female SCID mice bearing Sup-M2 subcutaneous tumor xenografts and nu / nu mice bearing HCT116 aged 6-8 week old [1] |
Dosage: | 3 mg/kg, 10 mg/kg and 30 mg/kg |
Administration: | oral gavage; twice a day; 12 days |
Result: | CEP-28122 produced dose-dependent antitumor activity in Sup-M2 subcutaneous tumor xenografts in SCID mice. In contrast, CEP-28122 had no antitumor activity in nu / nu mice bearing HCT116. |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : ≥ 6.4 mg/mL ( 10.08 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.5744 mL | 7.8719 mL | 15.7438 mL |
5 mM | 0.3149 mL | 1.5744 mL | 3.1488 mL |
10 mM | 0.1574 mL | 0.7872 mL | 1.5744 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.